Ran Nussbaum
CIK 1609805 · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KITE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2225 COLORADO AVENUE
SANTA MONICA, CA 90404
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LBRX | Director | 1,411,681 | $39.34 | $55.54M | $15.00M | 3 | 2026-06-05 |
| KROS | Director | 160,512 | $11.33 | $1.82M | $25.00M | 9 | 2025-06-11 |
| URGN | Director | 1,437,169 | $34.04 | $48.92M | $0 | 11 | 2023-02-28 |
| ELOX | Director | 8,363 | $13.17 | $110.1K | $13.21M | 9 | 2022-06-17 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | — | — | — | $0 | 1 | 2020-06-19 |
| Kite Pharma, Inc. (KITE) Delisted | Director | 7,880 | — | — | -$27.94M | 6 | 2017-06-22 |
Recent Filings · Page 5 of 6
53 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-05-22 | — | Buy (P) | +8,611 | $28.3K | |
| 2018-05-18 | — | Buy (P) | +8,611 | $28.3K | |
| 2018-05-10 | — | Grant (A) | — | $0 | |
| 2018-05-01 | ELOX | Buy (P) | +350,000 | $3.41M | EDGAR |
| 2018-03-23 | — | Buy (P) | +12,600 | $97.8K | |
| 2017-11-09 | — | Grant (A) | — | $0 | |
| 2017-10-05 | — | Disp (D) | −14,192 | $0 | |
| 2017-06-22 | Kite Pharma, Inc. (KITE) Delisted | Grant (A) | +2,410 | $0 | EDGAR |
| 2017-05-11 | Kite Pharma, Inc. (KITE) Delisted | Buy (P) | +9,832 | $679.5K | EDGAR |
| 2016-06-03 | Kite Pharma, Inc. (KITE) Delisted | Grant (A) | +1,950 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.